Inclusion Criteria:

- Histologically or cytologically proven solid tumour, refractory to conventional
treatment, or for which no conventional therapy exists or is declined by the patient
or for whom there is the prospect of clinical benefit

- Life expectancy of at least 12 weeks

- World Health Organisation (WHO) performance status of 0-2

- Haematological and biochemical indices within the ranges shown below. These
measurements must be performed within one week (Day -7 to Day 1) before the patient
receives AZD0424

- Haemoglobin (Hb) ≥ 9.0 g/dL

- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

- Platelet count ≥ 100 x 109/L

- Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x
(ULN) Either: Calculated creatinine clearance ≥ 50 mL/min Or Or Isotope
Clearance measurement ≥ 50 mL/min (uncorrected)

- 18 years or over

- Written (signed and dated) informed consent and be capable of co-operating with
treatment and follow-up

- MTD Expansion cohorts only: A tumour which is safely accessible for biopsy (single
and combination)

- Single Agent Expansion cohort only: patient must be willing and capable to have
[18F]FDGPET-CT imaging performed within two weeks of first AZD0424 administration and
again two weeks after first AZD0424 administration.

Exclusion Criteria:

- Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or
chemotherapy during the previous four weeks (six weeks for nitrosoureas, Mitomycin-C
and four weeks for investigational medicinal products) before treatment.

- Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia
or certain Grade 1 toxicities, which in the opinion of the Investigator and the DDO
should not exclude the patient.

- Symptomatic brain metastases (if brain metastases are present they must have been
stable for > 3 months).

- Patients with evidence of interstitial lung disease (bilateral, diffuse, parenchymal
lung disease).

- Patient with a history of auto-immune disease or a peanut allergy will be excluded.

- Ability to become pregnant (or already pregnant or lactating). However, those female
patients who have a negative serum or urine pregnancy test before enrollment and
agree to use two highly effective forms of contraception as detailed in the protocol
are considered eligible.

- Male patients with partners of child-bearing potential (unless they agree to take
measures not to father children by using one form of highly effective contraception
as detailed in the protocol). Men with pregnant or lactating partners should be
advised to use barrier method contraception (for example, condom plus spermicidal
gel) to prevent exposure to the foetus or neonate.

- Major thoracic or abdominal surgery from which the patient has not yet recovered.

- At high medical risk because of non-malignant systemic disease including active
uncontrolled infection.

- Known to be serologically positive for hepatitis B, hepatitis C or human
immunodeficiency virus (HIV).

- Resting ECG with measurable QTc interval of >480 msec (mean value and manually
verified) of at least 3 time points within a 24 hour period.

- Concurrent hypotension defined as a baseline supine blood pressure (BP) systolic < 90
mmHg.

- Concurrent congestive heart failure, prior history of class III/ IV cardiac disease
(New York Heart Association [NYHA]), prior history of cardiac ischaemia or prior
history of cardiac arrhythmia within 6 months. Coronary angioplasty or stenting in
the previous 12 months.

- Is a participant or plans to participate in another interventional clinical trial,
whilst taking part in this Phase Ia/Ib study of AZD0424 single agent and in
combination. Participation in an observational, counseling or psychological trial
would be acceptable.

- Any other condition which in the Investigator's opinion would not make the patient a
good candidate for the clinical trial.